Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Beeh, KM, Burgel, P-R, Franssen, FME, Lopez-Campos, JL, Loukides, S, Hurst, JR, Fležar, M, Ulrik, CS, Di Marco, F, Stolz, D, Valipour, A, Casserly, B, Ställberg, B, Kostikas, K & Wedzicha, JA 2017, 'How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?' American Journal of Respiratory and Critical Care Medicine, bind 196, nr. 2, s. 139-149. https://doi.org/10.1164/rccm.201609-1794CI

APA

Beeh, K. M., Burgel, P-R., Franssen, F. M. E., Lopez-Campos, J. L., Loukides, S., Hurst, J. R., ... Wedzicha, J. A. (2017). How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease? American Journal of Respiratory and Critical Care Medicine, 196(2), 139-149. https://doi.org/10.1164/rccm.201609-1794CI

CBE

Beeh KM, Burgel P-R, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, Fležar M, Ulrik CS, Di Marco F, Stolz D, Valipour A, Casserly B, Ställberg B, Kostikas K, Wedzicha JA. 2017. How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine. 196(2):139-149. https://doi.org/10.1164/rccm.201609-1794CI

MLA

Vancouver

Author

Beeh, Kai M ; Burgel, Pierre-Regis ; Franssen, Frits M E ; Lopez-Campos, Jose Luis ; Loukides, Stelios ; Hurst, John R ; Fležar, Matjaž ; Ulrik, Charlotte Suppli ; Di Marco, Fabiano ; Stolz, Daiana ; Valipour, Arschang ; Casserly, Brian ; Ställberg, Björn ; Kostikas, Konstantinos ; Wedzicha, Jadwiga A. / How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. I: American Journal of Respiratory and Critical Care Medicine. 2017 ; Bind 196, Nr. 2. s. 139-149.

Bibtex

@article{7e74a61ab20243c78b70d67b52f1329b,
title = "How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?",
abstract = "Decreasing the frequency and severity of exacerbations is one of the main goals of treatment for patients with chronic obstructive pulmonary disease (COPD). Several studies have documented that long-acting bronchodilators (LABDs) can reduce exacerbation rate and/or severity, and others have shown that combinations of long-acting 2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide greater reductions in exacerbation frequency than either their monocomponents or LABA/inhaled corticosteroids (LABA/ICS) combinations in patients at low and high risk for these events. In this review, small groups of experts critically evaluated mechanisms potentially responsible for the increased benefit of LABA/LAMA combinations over single LABDs or LABA/ICS in decreasing exacerbation. These included effects on lung hyperinflation and mechanical stress, inflammation, excessive mucus production with impaired mucociliary clearance, and symptom severity. The data assembled and analyzed by each group were reviewed by all authors and combined into this manuscript. Available clinical results support the possibility that effects of LABA/LAMA combinations on hyperinflation, mucociliary clearance, and symptom severity may all contribute to decreasing exacerbations. While preclinical studies suggest LABAs and LAMAs have anti-inflammatory effects, such effects have not been demonstrated yet in patients with COPD.",
author = "Beeh, {Kai M} and Pierre-Regis Burgel and Franssen, {Frits M E} and Lopez-Campos, {Jose Luis} and Stelios Loukides and Hurst, {John R} and Matjaž Fležar and Ulrik, {Charlotte Suppli} and {Di Marco}, Fabiano and Daiana Stolz and Arschang Valipour and Brian Casserly and Bj{\"o}rn St{\"a}llberg and Konstantinos Kostikas and Wedzicha, {Jadwiga A}",
year = "2017",
month = "7",
doi = "10.1164/rccm.201609-1794CI",
language = "English",
volume = "196",
pages = "139--149",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2",

}

RIS

TY - JOUR

T1 - How Do Dual Long-acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

AU - Beeh, Kai M

AU - Burgel, Pierre-Regis

AU - Franssen, Frits M E

AU - Lopez-Campos, Jose Luis

AU - Loukides, Stelios

AU - Hurst, John R

AU - Fležar, Matjaž

AU - Ulrik, Charlotte Suppli

AU - Di Marco, Fabiano

AU - Stolz, Daiana

AU - Valipour, Arschang

AU - Casserly, Brian

AU - Ställberg, Björn

AU - Kostikas, Konstantinos

AU - Wedzicha, Jadwiga A

PY - 2017/7

Y1 - 2017/7

N2 - Decreasing the frequency and severity of exacerbations is one of the main goals of treatment for patients with chronic obstructive pulmonary disease (COPD). Several studies have documented that long-acting bronchodilators (LABDs) can reduce exacerbation rate and/or severity, and others have shown that combinations of long-acting 2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide greater reductions in exacerbation frequency than either their monocomponents or LABA/inhaled corticosteroids (LABA/ICS) combinations in patients at low and high risk for these events. In this review, small groups of experts critically evaluated mechanisms potentially responsible for the increased benefit of LABA/LAMA combinations over single LABDs or LABA/ICS in decreasing exacerbation. These included effects on lung hyperinflation and mechanical stress, inflammation, excessive mucus production with impaired mucociliary clearance, and symptom severity. The data assembled and analyzed by each group were reviewed by all authors and combined into this manuscript. Available clinical results support the possibility that effects of LABA/LAMA combinations on hyperinflation, mucociliary clearance, and symptom severity may all contribute to decreasing exacerbations. While preclinical studies suggest LABAs and LAMAs have anti-inflammatory effects, such effects have not been demonstrated yet in patients with COPD.

AB - Decreasing the frequency and severity of exacerbations is one of the main goals of treatment for patients with chronic obstructive pulmonary disease (COPD). Several studies have documented that long-acting bronchodilators (LABDs) can reduce exacerbation rate and/or severity, and others have shown that combinations of long-acting 2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide greater reductions in exacerbation frequency than either their monocomponents or LABA/inhaled corticosteroids (LABA/ICS) combinations in patients at low and high risk for these events. In this review, small groups of experts critically evaluated mechanisms potentially responsible for the increased benefit of LABA/LAMA combinations over single LABDs or LABA/ICS in decreasing exacerbation. These included effects on lung hyperinflation and mechanical stress, inflammation, excessive mucus production with impaired mucociliary clearance, and symptom severity. The data assembled and analyzed by each group were reviewed by all authors and combined into this manuscript. Available clinical results support the possibility that effects of LABA/LAMA combinations on hyperinflation, mucociliary clearance, and symptom severity may all contribute to decreasing exacerbations. While preclinical studies suggest LABAs and LAMAs have anti-inflammatory effects, such effects have not been demonstrated yet in patients with COPD.

U2 - 10.1164/rccm.201609-1794CI

DO - 10.1164/rccm.201609-1794CI

M3 - Journal article

VL - 196

SP - 139

EP - 149

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2

ER -

ID: 49302575